<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">cardiotomsk</journal-id><journal-title-group><journal-title xml:lang="ru">Сибирский журнал клинической и экспериментальной медицины</journal-title><trans-title-group xml:lang="en"><trans-title>Siberian Journal of Clinical and Experimental Medicine</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2713-2927</issn><issn pub-type="epub">2713-265X</issn><publisher><publisher-name>TSU publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.29001/2073-8552-2025-40-3-57-67</article-id><article-id custom-type="elpub" pub-id-type="custom">cardiotomsk-2821</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КЛИНИЧЕСКИЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CLINICAL STUDIES</subject></subj-group></article-categories><title-group><article-title>Макрофагальная инфильтрация тканей оси «миокард-почка-селезенка-головной мозг» у пациентов с фатальным исходом инфаркт миокарда-ассоциированного шока</article-title><trans-title-group xml:lang="en"><trans-title>Macrophages of the of the axis “heart-spleen-brainkidney” in patients with fatal myocardial infarction complicated by cardiogenic shock</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1444-1037</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Керчева</surname><given-names>М. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Kercheva</surname><given-names>M. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Керчева Мария Анатольевна - канд. мед. наук, заведующий лабораторией инфаркт-ассоциированного шока, НИИ кардиологии Томского НИМЦ, Томск, Россия; доцент кафедры кардиологии, СибГМУ Минздрава России.</p><p>634012, Томск, ул. Киевская, 111а; 634050, Томск, Московский тракт, 2</p></bio><bio xml:lang="en"><p>Maria A. Kercheva - Cand. Sci. (Med.), Head of the Laboratory of Infarction-Associated Shock, Cardiology Research Institute, Tomsk NRMC, Tomsk, Russia; Associate Professor, Department of Cardiology, SSMU.</p></bio><email xlink:type="simple">mariiakercheva@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1281-3714</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гомбожапова</surname><given-names>А. Э.</given-names></name><name name-style="western" xml:lang="en"><surname>Gombozhapova</surname><given-names>A. E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Гомбожапова Александра Энхэевна - научный сотрудник, отделение неотложной кардиологии, НИИ кардиологии Томского НИМЦ; доцент кафедры кардиологии СибГМУ Минздрава России.</p><p>634012, Томск, ул. Киевская, 111а; 634050, Томск, Московский тракт, 2</p></bio><bio xml:lang="en"><p>Aleksandra A. Gombozhapova - Research Scientist, Department of Emergency Cardiology, Cardiology Research Institute, Tomsk NRMC, Tomsk, Russia; Associate Professor, Department of Cardiology, SSMU.</p><p>111a, Kievskaya str., Tomsk, 634012; 2, Moscovsky Trakt, Tomsk, 634055</p></bio><email xlink:type="simple">gombozhapova@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8543-6027</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Степанов</surname><given-names>И. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Stepanov</surname><given-names>I. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Степанов Иван Вадимович - канд. мед. наук, заведующий патологоанатомическим отделением, НИИ кардиологии Томского НИМЦ.</p><p>634012, Томск, ул. Киевская, 111а</p></bio><bio xml:lang="en"><p>Ivan V. Stepanov - Cand. Sci. (Med.), Head of the Pathology Department, Cardiology Research Institute, Cardiology Research Institute, Tomsk NRMC.</p><p>111a, Kievskaya str., Tomsk, 634012</p></bio><email xlink:type="simple">i_v_stepanov@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4358-7329</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Рябов</surname><given-names>В. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Ryabov</surname><given-names>V. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Рябов Вячеслав Валерьевич - д-р мед. наук, профессор, чл.-корр. РАН, заместитель директора по научной и лечебной работе, НИИ кардиологии Томского НИМЦ; заведующий кафедрой кардиологии, СибГМУ Минздрава России.</p><p>634012, Томск, ул. Киевская, 111а; 634050, Томск, Московский тракт, 2</p></bio><bio xml:lang="en"><p>Vyacheslav V. Ryabov - Dr. Sci. (Med.), Professor, Corresponding Member, Russian Academy of Siences, Deputy Director for Scientific and Medical Work, Cardiology Research Institute, Tomsk NRMC; Head of the Department of Cardiology, SSMU.</p><p>111a, Kievskaya str., Tomsk, 634012; 2, Moscovsky Trakt, Tomsk, 634055</p></bio><email xlink:type="simple">rvvt@cardiotomsk.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru">Научно-исследовательский институт кардиологии, Томский национальный исследовательский медицинский центр Российской академии наук (НИИ кардиологии Томского НИМЦ); Сибирский государственный медицинский университет Министерства здравоохранения Российской Федерации (СибГМУ Минздрава России)<country>Россия</country></aff><aff xml:lang="en">Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences (Cardiology Research Institute, Tomsk NRMC); Siberian State Medical University (SSMU)<country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru">Научно-исследовательский институт кардиологии, Томский национальный исследовательский медицинский центр Российской академии наук (НИИ кардиологии Томского НИМЦ)<country>Россия</country></aff><aff xml:lang="en">Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences (Cardiology Research Institute, Tomsk NRMC)<country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>05</day><month>10</month><year>2025</year></pub-date><volume>40</volume><issue>3</issue><fpage>57</fpage><lpage>67</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Керчева М.А., Гомбожапова А.Э., Степанов И.В., Рябов В.В., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Керчева М.А., Гомбожапова А.Э., Степанов И.В., Рябов В.В.</copyright-holder><copyright-holder xml:lang="en">Kercheva M.A., Gombozhapova A.E., Stepanov I.V., Ryabov V.V.</copyright-holder><license license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.sibjcem.ru/jour/article/view/2821">https://www.sibjcem.ru/jour/article/view/2821</self-uri><abstract><sec><title>Введение</title><p>Введение. Системная воспалительная реакция (СВР), возникающая в ответ на ишемию у пациентов с инфарктом миокарда (ИМ), − один из значимых механизмов патогенеза заболевания, определяющих его течение и исходы. Содержание одних из ключевых факторов процесса воспаления и регенерации – макрофагов (МФ) как в миокарде, так и в органах-мишенях, взаимосвязь концентрации прои противовоспалительных МФ в ранние и отдаленные сроки инфаркта с его неблагоприятными исходами остаются малоизученными.</p></sec><sec><title>Цель</title><p>Цель: комплексно изучить характеристики макрофагальной инфильтрации тканей миокарда, почек, головного мозга (ГМ) и селезенки у пациентов, умерших от инфаркт миокарда-ассоциированного шока (ИМ КШ), охарактеризовать их связь с клиническим портретом пациентов.</p></sec><sec><title>Материал и методы</title><p>Материал и методы. Были исследованы фрагменты селезенки (красная (КП) и белая пульпа (БП)), миокарда, почек и ГМ, забранные во время аутопсии пациентов, умерших от ИМ КШ (n = 25). Макрофагальную инфильтрацию тканей оценивали с помощью иммуногистохимического анализа с использованием антител к общему маркеру МФ – CD68 и к маркерам МФ М2 – CD163, CD206, стабилину-1.</p></sec><sec><title>Результаты</title><p>Результаты. Максимальное и неизменно высокое относительно раннего к отдаленному периоду ИМ содержание всех исследуемых клеток обнаружено в КП селезенки: CD68+ 898 (807; 1049), CD163+ 898 (807; 1049), стабилин-1+ 807 (526; 985), CD206+ 11 (9; 19) клеток. В инфарктной зоне (ИЗ) миокарда, концентрация всех исследуемых клеток возрастала: CD68+ – от 59 (52; 95) до 376 (136; 634), CD163+ – от 82 (34; 285) до 697 (545; 982), CD206+ – от 21 (12; 43) до 99 (31; 249), стабилин-1+ – от 0 (0; 1) до 126 клеток (p &lt; 0,05). Единственный тип клеток среди изученных нами и показавший снижение своей концентрации к отдаленному периоду ИМ – CD206+ клетки в почках: от 6 (5; 8) до 2 (1; 2) (p &lt; 0,005). При анализе межорганных корреляций выявлено большое количество взаимодействий между органами на клеточном уровне, преимущественно в ранний постинфарктный период. Количество CD163+ клеток в ГМ коррелирует с возрастом (r = –0,7, p = 0,0006).</p></sec><sec><title>Выводы</title><p>Выводы. Комплексный анализ макрофагальной инфильтрации тканей – миокарда, почек, ГМ и селезенки у пациентов с фатальным ИМ КШ показал, что максимальное, неизменно высокое содержание исследуемых клеток (CD68+, CD163+, CD206+, стабилин-1+) характерно для одного из ведущих органов иммуногенеза – селезенки. Активное течение СВР на уровне миокарда у лиц с ИМ КШ нашло свое отражение в повышении содержания всех исследуемых типов клеток в ИЗ миокарда. Снижение регенераторных возможностей организма при ИМ КШ отразилось в снижении содержания количества CD206+ клеток в почках. Большое количество межорганных взаимосвязей между клетками макрофагального ряда в раннем периоде ИМ, а также наличие связей между концентрацией макрофагальных клеток в тканях и клиническими данными подтверждают ценность проведения последующего комплексного анализа клеточного состава ткани инфарцированного миокарда в сочетании с динамикой уровня сывороточных маркеров, отражающих активность СВР у пациентов с ИМ КШ.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Introduction</title><p>Introduction. The systemic inflammatory response (SIR) that occurs in response to ischemia in patients with myocardial infarction (MI) is one of the significant mechanisms of the pathogenesis of this disease, determining its course and outcomes. The content of one of the key factors in the inflammation and regeneration process – macrophages (MFs), both in the myocardium and in target organs, as well as the relationship between the concentration of proand anti-inflammatory MFs in the early and late stages of infarction with its adverse outcomes remain poorly understood.</p></sec><sec><title>Aim</title><p>Aim: To comprehensively study the characteristics of macrophage infiltration of myocardial tissue, kidneys, brain and spleen in patients who died from myocardial infarction-associated shock (MI CS), and to characterize their relationship with the clinical profile of the patient.</p></sec><sec><title>Material and Methods</title><p>Material and Methods. We included 25 patients with fatal MI CS. We examined fragments of spleens (red (RP) and white pulp (WP)), myocardium, kidneys and brain taken during the autopsy. Macrophage infiltration of the tissues was assessed by immunohistochemistry with usage of antibodies for the general marker of MFs – CD68 and to the M2 MFs markers – CD163, CD206, Stabilin-1.</p></sec><sec><title>Results</title><p>Results. The maximum count of all studied cells was found in the RP: CD68+ 898 (807; 1049), CD163+ 898 (807; 1049), stabilin 1+ 807 (526; 985), CD206+ 11 (9; 19) cells. However, the content of all the studied cells in the RP and WP remained consistently high relative from the early to the late period of MI. In the myocardial (infarcted area), on the contrary, the concentration of all the studied cells increased relative from the early to the late period of MI: CD68+ from 59 (52; 95) to 376 (136; 634), CD163+ from 82 (34; 285) to 697 (545; 982), CD206+ from 21 (12; 43) to 99 (31; 249), stabilin-1+ from 0 (0; 1) to 126 cells (p &lt; 0.05). The only cell type among those studied by us that showed a decrease in its concentration relative to the early to the late period of MI were CD206+ cells in the kidneys: from 6 (5; 8) to 2 (1; 2) (p &lt; 0.005). When analyzing interorgan correlations, attention is drawn to the large number of interorgan interactions at the cellular level, mainly in the early post-infarction period. The correlation was shown between CD163+ cells in brain and age (r = –0.7, p = 0.0006).</p></sec><sec><title>Conclusions</title><p>Conclusions. A comprehensive analysis of macrophage infiltration of myocardium, kidneys, brain and spleen in patients with fatal MI CS showed that the maximum, consistently high content of the studied cells – CD68+, CD163+, CD206+, stabilin-1+ is characteristic of one of the leading organs of immunogenesis the spleen. The active course of SIR in the myocardium in patients with MI was reflected in an increase in the content of all studied cell types in the infarct area of myocardium, while a decrease in the regenerative capacity in patients with MI was reflected in a decrease in the content of CD206+ cells in the kidneys. A large number of interorgan relationships between MFs in the early period of MI, as well as the presence of relationships between the concentration of MFs in tissues and clinical data, confirms the value of conducting a subsequent comprehensive analysis of the cellular composition of infarcted myocardial tissue in combination with the dynamics of the level of serum markers reflecting the activity of the SIR in patients with MI CS.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>инфаркт миокарда</kwd><kwd>кардиогенный шок</kwd><kwd>макрофаги</kwd></kwd-group><kwd-group xml:lang="en"><kwd>myocardial infarction</kwd><kwd>cardiogenic shock</kwd><kwd>macrophages</kwd></kwd-group><funding-group xml:lang="ru"><funding-statement>государственное задание на оказание государственных услуг (выполнение работ) № 07500712-24-04 от 02.04.2024 г.</funding-statement></funding-group><funding-group xml:lang="en"><funding-statement>state assignment for the provision of public services (performance of work) №075-00712-24-04 dated 04.02.2024, laboratory of infarction-associated shock.</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Ong S.B., Hernández-Reséndiz S., Crespo-Avilan G.E. Mukhametshina R.T., Kwek X.Y., Cabrera-Fuentes H.A. et al. Inflammation following acute myocardial infarction: Multiple players, dynamic roles, and novel therapeutic opportunities. Pharmacol. Ther. 2018;186:73–87. https://doi.org/10.1016/j.pharmthera.2018.01.001.</mixed-citation><mixed-citation xml:lang="en">Ong 	S.B., 	Hernández-Reséndiz 	S., 	Crespo-Avilan 	G.E. Mukhametshina R.T., Kwek X.Y., Cabrera-Fuentes H.A. et al. Inflammation following acute myocardial infarction: Multiple players, dynamic roles, and novel therapeutic opportunities. Pharmacol. Ther. 2018;186:73–87. https://doi.org/10.1016/j.pharmthera.2018.01.001.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Kologrivova I., Shtatolkina M., Suslova T., Ryabov V. Cells of the immune system in cardiac remodeling: main players in resolution of inflammation and repair after myocardial infarction. Front. Immunol. 2021;12:664457. https://doi.org/10.3389/fimmu.2021.664457.</mixed-citation><mixed-citation xml:lang="en">Kologrivova I., Shtatolkina M., Suslova T., Ryabov V. Cells of the immune system in cardiac remodeling: main players in resolution of inflammation and repair after myocardial infarction. Front. Immunol. 2021;12:664457. https://doi.org/10.3389/fimmu.2021.664457.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Halade G.V., Norris P.C., Kain V., Serhan C.N., Ingle K.A. Splenic leukocytes define the resolution of inflammation in heart failure. Sci. Signal. 2018;11(520):eaao1818. https://doi.org/10.1126/scisignal.aao1818.</mixed-citation><mixed-citation xml:lang="en">Halade G.V., Norris P.C., Kain V., Serhan C.N., Ingle K.A. Splenic leukocytes define the resolution of inflammation in heart failure. Sci. Signal. 2018;11(520):eaao1818. https://doi.org/10.1126/scisignal.aao1818.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Nahrendorf M., Pittet M.J., Swirski F.K. Monocytes: protagonists of infarct inflammation and repair after myocardial infarction. Circulation. 2010;121(22):2437–2445. https://doi.org/10.1161/CIRCULATIONAHA.109.916346.</mixed-citation><mixed-citation xml:lang="en">Nahrendorf M., Pittet M.J., Swirski F.K. Monocytes: protagonists of infarct inflammation and repair after myocardial infarction. Circulation. 2010;121(22):2437–2445. https://doi.org/10.1161/CIRCULATIONAHA.109.916346.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Matter M.A., Paneni F., Libby P., Frantz S., Stähli B.E., Templin C. et al. Inflammation in acute myocardial infarction: the good, the bad and the ugly. Eur. Heart J. 2024;45(2):89–103. https://doi.org/10.1093/eurheartj/ehad486.</mixed-citation><mixed-citation xml:lang="en">Matter M.A., Paneni F., Libby P., Frantz S., Stähli B.E., Templin C. et al. Inflammation in acute myocardial infarction: the good, the bad and the ugly. Eur. Heart J. 2024;45(2):89–103. https://doi.org/10.1093/eurheartj/ehad486.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Huang S., Frangogiannis N.G. Anti-inflammatory therapies in myocardial infarction: failures, hopes and challenges. Br. J. Pharmacol. 2018;175(9):1377–1400. https://doi.org/10.1111/bph.14155.</mixed-citation><mixed-citation xml:lang="en">Huang S., Frangogiannis N.G. Anti-inflammatory therapies in myocardial infarction: failures, hopes and challenges. Br. J. Pharmacol. 2018;175(9):1377–1400. https://doi.org/10.1111/bph.14155.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Kapur N.K., Thayer K.L., Zweck E. Cardiogenic shock in the setting of acute myocardial infarction. Methodist DeBakey Cardiovasc. J. 2020;16(1):16–21. https://doi.org/10.14797/mdcj-16-1-16.</mixed-citation><mixed-citation xml:lang="en">Kapur N.K., Thayer K.L., Zweck E. Cardiogenic shock in the setting of acute myocardial infarction. Methodist DeBakey Cardiovasc. J. 2020;16(1):16–21. https://doi.org/10.14797/mdcj-16-1-16.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Пантелеев О.О., Рябов В.В. Кардиогенный шок – что нового? Сибирский журнал клинической и экспериментальной медицины. 2021;36(4):45–51. https://doi.org/10.29001/2073-8552-2021-36-4-4551.</mixed-citation><mixed-citation xml:lang="en">Panteleev O.O., Ryabov V.V. Cardiogenic shock: What’s new? Siberian Journal of Clinical and Experimental Medicine. 2021;36(4):45–51. (In Russ). https://doi.org/10.29001/2073-8552-2021-36-4-45-51.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Geppert A., Huber K. Inflammation and cardiovascular diseases: lessons that can be learned for the patient with cardiogenic shock in the intensive care unit. Curr. Opin. Crit. Care. 2004;10(5):347–353. https://doi.org/10.1097/01.ccx.0000139364.53198.fd.</mixed-citation><mixed-citation xml:lang="en">Geppert A., Huber K. Inflammation and cardiovascular diseases: lessons that can be learned for the patient with cardiogenic shock in the intensive care unit. Curr. Opin. Crit. Care. 2004;10(5):347–353. https://doi.org/10.1097/01.ccx.0000139364.53198.fd.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Heusch G. The spleen in myocardial infarction. Circ. Res. 2019;124(1):26–28. https://doi.org/10.1161/CIRCRESAHA.118.314331.</mixed-citation><mixed-citation xml:lang="en">Heusch G. The spleen in myocardial infarction. Circ. Res. 2019;124(1):26–28. https://doi.org/10.1161/CIRCRESAHA.118.314331.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Керчева М.А., Рябов В.В., Гомбожапова А.Э., Трусов А.А., Степанов И.В., Кжышковска Ю.Г. Место кардиоспленальной оси в развитии фатального исхода инфаркта миокарда. Российский кардиологи ческий журнал 2023-5411. https://doi.org/10.15829/1560-4071-2023-5411.</mixed-citation><mixed-citation xml:lang="en">Kercheva M.A., Ryabov V.V., Gombozhapova A.Е., Trusov A.A., Stepanov I.V., Kzhyshkowska Yu.G. Place of the cardiosplenic axis in the development of fatal myocardial infarction. Russian Journal of Cardiology. 2023;28(5):5411. (In Russ.). https://doi.org/10.15829/15604071-2023-5411.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Керчева М.А., Рябов В.В., Ребенкова М.С., Ким Б., Рябцева А.Н., Колмаков А.А., Гомбожапова А.Э., Кжышковска Ю.Г. Особенности макрофагальной инфильтрации почек у пациентов с инфарктом миокарда. Сибирский журнал клинической и экспериментальной медицины. 2021;36(2):61–69. https://doi.org/10.29001/2073-8552-202136-2-61-69.</mixed-citation><mixed-citation xml:lang="en">Kercheva M.A., Ryabov V.V., Rebenkova M.S., Kim B., Ryabtseva A.N., Kolmakov A.A., Gombozhapova A.E., Kzhyshkowska J.G. Features of renal macrophage infiltration in patients with myocardial infarction. Siberian Journal of Clinical and Experimental Medicine. 2021;36(2):61– 69. (In Russ.) https://doi.org/10.29001/2073-8552-2021-36-2-61-69.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Fujiu K., Shibata M., Nakayama Y., Ogata F., Matsumoto S., Noshita K. et al. A heart-brain-kidney network controls adaptation to cardiac stress through tissue macrophage activation. Nat. Med. 2017;23(5):611–622. https://doi.org/10.1038/nm.4326.</mixed-citation><mixed-citation xml:lang="en">Fujiu K., Shibata M., Nakayama Y., Ogata F., Matsumoto S., Noshita K. et al. A heart-brain-kidney network controls adaptation to cardiac stress through tissue macrophage activation. Nat. Med. 2017;23(5):611–622. https://doi.org/10.1038/nm.4326.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Thygesen K., Alpert J.S., Jaffe A.S., Chaitman B.R., Bax J.J., Morrow D.A. et al. Fourth Universal Definition of Myocardial Infarction (2018). J. Am. Coll. Cardiol. 2018;72(18):2231–2264. https://doi.org/10.1016/j.jacc.2018.08.1038.</mixed-citation><mixed-citation xml:lang="en">Thygesen K., Alpert J.S., Jaffe A.S., Chaitman B.R., Bax J.J., Morrow D.A. et al. Fourth Universal Definition of Myocardial Infarction (2018). J. Am. Coll. Cardiol. 2018;72(18):2231–2264. https://doi.org/10.1016/j.jacc.2018.08.1038.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Ponikowski P., Voors A.A., Anker S.D., Bueno H., Cleland J.G.F., Coats A.J.S. et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur. Heart J. 2016;37(27):2129– 2200. https://doi.org/10.1093/eurheartj/ehw128.</mixed-citation><mixed-citation xml:lang="en">Ponikowski P., Voors A.A., Anker S.D., Bueno H., Cleland J.G.F., Coats A.J.S. et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur. Heart J. 2016;37(27):2129– 2200. https://doi.org/10.1093/eurheartj/ehw128.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Jäckel M., Zotzmann V., Wengenmayer T., Duerschmied D., Biever P.M., Spieler D., et al. Incidence and predictors of delirium on the intensive care unit after acute myocardial infarction, insight from a retrospective registry. Catheter. Cardiovasc. Interv. 2021;98(6):1072–1081. https://doi.org/10.1002/ccd.29275.</mixed-citation><mixed-citation xml:lang="en">Jäckel M., Zotzmann V., Wengenmayer T., Duerschmied D., Biever P.M., Spieler D., et al. Incidence and predictors of delirium on the intensive care unit after acute myocardial infarction, insight from a retrospective registry. Catheter. Cardiovasc. Interv. 2021;98(6):1072–1081. https://doi.org/10.1002/ccd.29275.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Moras E., Yakkali S., Gandhi K.D., Virk H.U.H., Alam M., Zaid S. et al. Complications in acute myocardial infarction: navigating challenges in diagnosis and management. Hearts. 2024;5(1):122–141. https://doi.org/10.3390/hearts5010009.</mixed-citation><mixed-citation xml:lang="en">Moras E., Yakkali S., Gandhi K.D., Virk H.U.H., Alam M., Zaid S. et al. Complications in acute myocardial infarction: navigating challenges in diagnosis and management. Hearts. 2024;5(1):122–141. https://doi.org/10.3390/hearts5010009.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Kzhyshkowska J. Multifunctional receptor stabilin-1 in homeostasis and disease. Sci. World J. 2010;10:2039–2042. https://doi.org/10.1100/tsw.2010.189.</mixed-citation><mixed-citation xml:lang="en">Kzhyshkowska J. Multifunctional receptor stabilin-1 in homeostasis and disease. Sci. World J. 2010;10:2039–2042. https://doi.org/10.1100/tsw.2010.189.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Chistiakov D.A., Killingsworth M.C., Myasoedova V.A., Orekhov A.N., Bobryshev Y.V. CD68/macrosialin: Not just a histochemical marker. Lab. Invest. 2017;97:4–13. https://doi.org/10.1038/labinvest.2016.116.</mixed-citation><mixed-citation xml:lang="en">Chistiakov D.A., Killingsworth M.C., Myasoedova V.A., Orekhov A.N., Bobryshev Y.V. CD68/macrosialin: Not just a histochemical marker. Lab. Invest. 2017;97:4–13. https://doi.org/10.1038/labinvest.2016.116.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Fischer-Riepe L., Daber N., Schulte-Schrepping J., Véras De Carvalho B.C., Russo A., Pohlen M. et al. CD163 expression defines specific, IRF8-dependent, immune-modulatory macrophages in the bone marrow. J. Allergy Clin. Immunol. 2020;146(5):1137–1151. https://doi.org/10.1016/j.jaci.2020.02.034.</mixed-citation><mixed-citation xml:lang="en">Fischer-Riepe L., Daber N., Schulte-Schrepping J., Véras De Carvalho B.C., Russo A., Pohlen M. et al. CD163 expression defines specific, IRF8-dependent, immune-modulatory macrophages in the bone marrow. J. Allergy Clin. Immunol. 2020;146(5):1137–1151. https://doi.org/10.1016/j.jaci.2020.02.034.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
